NEW DELHI, June 9. /Dunyo IA/. Uzbekistan is accelerating cooperation with India in the fields of pharmaceuticals, biotechnology, and nutraceuticals as part of its strategy to transform the country into a major manufacturing and export hub for the CIS and Eurasian markets.

An article on this topic was published by the Indian business portal “Business Standard”, reports Dunyo IA correspondent.

The author of the article, Anjali Singh, referencing Abdulla Azizov, the Director of the Agency for the Development of the Medical and Pharmaceutical Industry of Uzbekistan, emphasizes that the country has set an ambitious goal to increase its pharmaceutical production volume from 620 million US dollars in 2025 to 10 billion dollars by 2035.

This target reflects the steady growth of the sector. Over the past two years, production has expanded by nearly 80%, rising from 340 million dollars in 2023 to approximately 620 million dollars by the end of last year. The publication notes that this dynamic trajectory is the result of consistent policies focused on localization, attracting foreign investment, and fostering an export-oriented approach.

Uzbekistan's strategic vision goes beyond simple import substitution. “We want to become a hub for manufacturing and exporting to the CIS region”, - the publication quotes Abdulla Azizov, who invited Indian companies to use Uzbekistan as a “strategic bridge” to Central Asian and Eurasian markets. The CIS pharmaceutical market volume is estimated at 57 billion dollars, and Uzbekistan, which maintains a free trade regime with its countries, offers Indian manufacturers an efficient channel of access to this vast consumer base.

For Indian investors, an unprecedented favorable regime has been established, including 10-year tax incentives in specialized pharmaceutical free economic zones (FEZs), land cost subsidies, customs duty exemptions, developed infrastructure, cost compensation for international registration of medicines and more, the media outlet concludes.

The partnership builds on results already achieved. A number of Indian companies have already invested in setting up production facilities in Uzbekistan, and negotiations with other potential partners are in an active stage.

An important step was the launch this year of a structured Uzbek-Indian pharmaceutical and nutraceutical trade corridor, designed to expand access to the wider Eurasian healthcare market, the volume of which is estimated at 7–10 billion dollars, “Business Standard” portal emphasizes.